I highly recommend this new blog post by Ada Nguyen to help people make sense of the longevity biotech world, and for people to understand more generally where the longevity therapeutics field is focused, and to help people understand the new drugs and therapies that are in development.
Ada was a valuable contributor to VitaDAO, has worked as a consultant in the cellular rejuvenation part of the longevity field, and is now working on her own new longevity biotech therapeutics company.
Navigating the idea maze of longevity biotech can be a daunting task. Although comprehensive databases like Longevity List and AgingBiotech.info offer valuable information on various companies, it is still challenging to see the big picture and identify established or unexplored paths. To pinpoint such areas, it’s important to know what strategies there are and which have not been explored commercially – information not reflected in the databases.
To address these challenges, this post aims to provide a survey of all different scientific approaches in longevity biotech. Beginning with a broad overview of the entire landscape, we will delve deeper into each approach and scope out under-explored areas with promising potential.
Table of Contents
- 1. Landscape overview
- 2. Reset and repair
- 3. Replace
- 4. Reprogram
- 5. Discovery
7 Likes
A news story on the Longevity Biotech market:
According to de Magalhães, there are more than 2,000 genes that modulate longevity and over 1,000 drugs and compounds that are associated with slowing the aging process. He stated that “Resveratrol, rapamycin, and metformin are the most studied longevity drugs, but the lifespan effects are much greater and more consistent for rapamycin than for resveratrol so this is of growing interest.
1 Like
From today’s RockHealth newsletter (San Francisco-based healthcare investment group)
February 3, 2025
There’s growing fascination with (and funding for) longevity innovation—a field intended to increase lifespan and healthspan by preventing the onset of age-related conditions. Retro Biosciences, a startup leveraging OpenAI technology to develop longevity therapies, announced it’s raising $1B “to extend the human lifespan by a decade.” Hone Health, a direct-to-consumer telehealth player focused on hormone optimization, secured $33M in Series A funding to expand into longevity care. Meanwhile, longevity’s “sister” focus area preventative healthsaw Neko Health, a full-body scan startup, secure a whopping $260M in Series B funding. At the same time, virtual weight loss platform Noom brought AI body scan features onto its mobile app—building off of existing tailwinds in weight lossand food as medicine.
From waiting lists to high price tags, the emerging product market for longevity raises critical questions about accessibility—and exactly who benefits from breakthroughs. High-cost, direct-to-consumer models could widen health disparities instead of closing healthspan-lifespan gaps. And it goes without saying that aging care innovation is still very much needed to address the immediateneeds and care accessibility challenges of an aging population. All in all, healthcare innovators are making it clear that aging is no longer a passive process or inevitability—it’s an industry.
